Advertisement
Home Tags Respiratory Problems: Misc.

Tag: Respiratory Problems: Misc.

Use of ex vivo lung perfusion-treated lungs increases the number of patients undergoing transplantation with comparable long-term outcomes

Lung Transplant With Ex Vivo Lung Perfusion Feasible

Method increases number of available lungs with comparable patient outcomes
Juul

Juul Stopping Sales of Fruit, Dessert Flavors of E-Cigarettes

Flavors dropped by Juul include mango, creme, fruit, and cucumber, which account for 10 percent of its sales
In an early-release Oct. 11 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report

CDC Releases Clinical Guidance on E-Cigarette Lung Injury

Guidelines highlight importance of asking patients about e-cigarette, or vaping, use in nonjudgmental way
The number of Americans sickened with a severe lung injury tied to vaping just keeps rising

Close to 1,300 Cases of Vaping-Linked Illness Now Identified

And, 26 vaping-related deaths across 21 states have now been reported
Active acute respiratory illness surveillance can be implemented among patients and staff in an adult long-term care facility

Acute Respiratory Viral Illness Surveillance Possible in Long-Term Care

Data revealed many health care personnel who reported an illness said they worked when sick
The number of Americans sickened with a severe lung illness tied to vaping continues to climb

Cases of Serious Vaping-Linked Lung Injury Now Top 1,000

New England Journal of Medicine article presents lung histopathology findings from recent cases

September 2019 Briefing – Pulmonology

Here are what the editors at HealthDay consider to be the most important developments in Pulmonology for September 2019. This roundup includes the latest...
On Monday

Juul Halts Funding for San Francisco Vaping Ballot Initiative

News comes as Nebraska sees first vaping-related death; U.S. total now 15
Compared with placebo

No Benefit Found for High-Dose Vitamin C Infusions in Sepsis, ARDS

No differences seen versus placebo in organ dysfunction scores, biomarkers of inflammation or vascular injury
For patients with progressive fibrosing interstitial lung diseases

Nintedanib Slows Fibrosing Interstitial Lung Disease

Nintedanib linked to lower rate of decline in forced vital capacity versus placebo in phase 3 trial